Addex names new CEO; Chugai nabs Japanese rights to vemurafenib; Icagen investors claim value closer to $165M;

@FierceBiotech: MA-based Proteon Therapeutics has raised $15.2M in an equity and options financing. Item | Follow @FierceBiotech

@JohnCFierce: Generic drug makers agree to program in which they pay an initial $299M to speed up FDA reviews, clear a backlog. Story | Follow @JohnCFierce

@RyanMFierce: Broad Institute CIO says genome research outfit on way to filling 10-petabyte capacity. Interview | Follow @RyanMFierce

@MaureenFierce: MIT's Lincoln Lab researchers have developed tech that may someday cure the any virus. Report | Follow @MaureenFierce

> Switzerland's Addex Pharmaceuticals has tapped Dr. Bharatt Chowrira as its new CEO. He had been a senior VP and COO at Nektar. Release

> Chugai has nabbed the Japanese marketing rights to the melanoma drug vemurafenib from Roche. Chugai plans to start a Phase I in 2012. Release

> Some of the Icagen investors trying to block Pfizer's $50 million deal to buy up the biotech say the company could actually be worth up to $165 million. Story

Pharma News

@FiercePharma: J&J chief gets chance to advise Obama on job creation. How about this: Avoid recalls, Mr. President. Article | Follow @FiercePharma

> J&J, AZ nix Facebook pages on commenting rule change. Article

> Pfizer wins patent case against Teva. News

Biotech IT News

> Accelyrs' revenue Q2 up 86% after mergers. Report

> New CIO reach tackles IT needs at the Broad Institute. More

> Virtual rats in the works to aid disease research. Details

> Perceptive Informatics does part in Parexel's losing Q4. Story

> BMS taps GNS Healthcare for computer model of information. News

> Medidata sees CFO resign after Q2 growth. Article

Medical Device News

> Device industry sees more investment, fewer deals. Details

> Sen. Brown visits Covidien, lobbies against device tax. News

> Southern Diagnostic Laboratories bought by Solstas. Story

> NEJM authors come out in support of IOM report. Article

And Finally... Researchers at the University of York have won $3.5 million to fund their work on prostate cancer stem cells. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.